Cite
MLA Citation
N. Kiyota et al.. “2864 Defining 131I-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by 131I-refractory criteria in the SELECT trial.” European journal of cancer, vol. 51, n.d., pp. S578–. http://access.bl.uk/ark:/81055/vdc_100030628283.0x000035